SLC5A2 and chronic kidney disease: Existing treatments, including renin-angiotensin system (RAS) inhibitors, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 (SGLT2) blockers, can slow down the advancement of CKD, but their antifibrotic effects are limited and subject to significant individual differences (Cooper et al., 2023; Folkerts et al., 2023; Dekkers and Gansevoort, 2020).